Cargando…

Integrated Analyses Identify Immune-Related Signature Associated with Qingyihuaji Formula for Treatment of Pancreatic Ductal Adenocarcinoma Using Network Pharmacology and Weighted Gene Co-Expression Network

The study aimed to clarify the potential immune-related targets and mechanisms of Qingyihuaji Formula (QYHJ) against pancreatic cancer (PC) through network pharmacology and weighted gene co-expression network analysis (WGCNA). Active ingredients of herbs in QYHJ were identified by the TCMSP database...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qian, Xiang, Chen, Zhuo, Chen, Sha Sha, Liu, Lu Ming, Zhang, Ai Qin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256764/ https://www.ncbi.nlm.nih.gov/pubmed/32537471 http://dx.doi.org/10.1155/2020/7503605

Ejemplares similares

Qingyihuaji Formula Inhibits Pancreatic Cancer and Prolongs Survival by Downregulating Hes-1 and Hey-1
por: Xu, Yanli, et al.
Publicado: (2015)

Nanog Predicts Poor Prognosis in Human Pancreatic Cancer and Is Downregulated by QingyihuaJi Formula in Pancreatic Cancer Stem Cells
por: Gao, Song, et al.
Publicado: (2016)

Retracted: Qingyihuaji Formula Inhibits Pancreatic Cancer and Prolongs Survival by Downregulating Hes-1 and Hey-1
por: Alternative Medicine, Evidence-Based Complementary and
Publicado: (2021)

Qingyihuaji formula reverses gemcitabine resistant human pancreatic cancer through regulate lncRNA AB209630/miR-373/EphB2-NANOG signals
por: Chen, Peng, et al.
Publicado: (2019)

Proteomic analyses identify prognostic biomarkers for pancreatic ductal adenocarcinoma
por: Hu, Dingyuan, et al.
Publicado: (2018)

Galectins Are Central Mediators of Immune Escape in Pancreatic Ductal Adenocarcinoma
por: Jiang, Zhengting, et al.
Publicado: (2022)

Identification of a robust functional subpathway signature for pancreatic ductal adenocarcinoma by comprehensive and integrated analyses
por: Wang, Ping, et al.
Publicado: (2020)

The limits of molecular signatures for pancreatic ductal adenocarcinoma subtyping
por: Lautizi, Manuela, et al.
Publicado: (2022)

Analysis of dynamic molecular networks for pancreatic ductal adenocarcinoma progression
por: Pan, Zongfu, et al.
Publicado: (2018)

Network Pharmacology-Based Prediction of Mechanism of Shenzhuo Formula for Application to DKD
por: Wang, Xinmiao, et al.
Publicado: (2021)

Prognostic Fifteen-Gene Signature for Early Stage Pancreatic Ductal Adenocarcinoma
por: Chen, Dung-Tsa, et al.
Publicado: (2015)

Ion Channel Signature in Healthy Pancreas and Pancreatic Ductal Adenocarcinoma
por: Schnipper, Julie, et al.
Publicado: (2020)

Correction to: Analysis of dynamic molecular networks for pancreatic ductal adenocarcinoma progression
por: Pan, Zongfu, et al.
Publicado: (2020)

Is there a CDKN2A-centric network in pancreatic ductal adenocarcinoma?
por: Wu, Chu, et al.
Publicado: (2020)

A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma
por: Haider, Syed, et al.
Publicado: (2014)

Identifying the neck margin status of ductal adenocarcinoma in the pancreatic head by multiphoton microscopy
por: Xu, Jian, et al.
Publicado: (2017)

Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis
por: Mayerle, Julia, et al.
Publicado: (2018)

Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review
por: Koltai, Tomas, et al.
Publicado: (2022)

Integrated analysis of circular RNA-associated ceRNA network in pancreatic ductal adenocarcinoma
por: Song, Wei, et al.
Publicado: (2020)

Development and Verification of the Hypoxia- and Immune-Associated Prognostic Signature for Pancreatic Ductal Adenocarcinoma
por: Chen, Dongjie, et al.
Publicado: (2021)

Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma
por: Tong, Yexin, et al.
Publicado: (2022)

The immune escape signature predicts the prognosis and immunotherapy sensitivity for pancreatic ductal adenocarcinoma
por: Lu, Hao, et al.
Publicado: (2022)

Investigating the Mechanisms of Bisdemethoxycurcumin in Ulcerative Colitis: Network Pharmacology and Experimental Verification
por: Wu, Huihuan, et al.
Publicado: (2022)

Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma
por: Tang, Rong, et al.
Publicado: (2021)

Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma
por: Shao, Feng, et al.
Publicado: (2018)

Establishing and validating an ADCP-related prognostic signature in pancreatic ductal adenocarcinoma
por: Zhang, Deyu, et al.
Publicado: (2022)

Novel prognostic gene signature for pancreatic ductal adenocarcinoma based on hypoxia
por: Ren, Min, et al.
Publicado: (2023)

Desmoplastic stromal signatures predict patient outcomes in pancreatic ductal adenocarcinoma
por: Mascharak, Shamik, et al.
Publicado: (2023)

Dysregulated miRNAs modulate tumor microenvironment associated signaling networks in pancreatic ductal adenocarcinoma
por: Liu, Tiantian, et al.
Publicado: (2023)

Identification of genes and pathways associated with pancreatic ductal adenocarcinoma by bioinformatics analyses
por: LONG, JIN, et al.
Publicado: (2016)

Correction: Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis
Publicado: (2018)

Identification of an unfolded protein response-related signature for predicting the prognosis of pancreatic ductal adenocarcinoma
por: Fang, Lishan, et al.
Publicado: (2023)

Proteome alterations in pancreatic ductal adenocarcinoma
por: Pan, Sheng, et al.
Publicado: (2020)

Repurposing econazole as a pharmacological autophagy inhibitor to treat pancreatic ductal adenocarcinoma
por: Weng, Ningna, et al.
Publicado: (2022)

Integrated analysis of Dendrobium nobile extract Dendrobin A against pancreatic ductal adenocarcinoma based on network pharmacology, bioinformatics, and validation experiments
por: Xu, Xiaoqing, et al.
Publicado: (2023)

High expression of erythropoietin-producing hepatoma cell line-B2 (EphB2) predicts the efficiency of the Qingyihuaji formula treatment in pancreatic cancer CFPAC-1 cells through the EphrinB1-EphB2 pathway
por: HUA, YONG-QIANG, et al.
Publicado: (2014)

MicroRNA modulated networks of adaptive and innate immune response in pancreatic ductal adenocarcinoma
por: Felix, Tainara F., et al.
Publicado: (2019)

Unraveling ERBB network dynamics upon betacellulin signaling in pancreatic ductal adenocarcinoma in mice
por: Hedegger, Kathrin, et al.
Publicado: (2020)

Mimics of pancreatic ductal adenocarcinoma
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Pancreatic ductal adenocarcinoma staging
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_kpv0npum1bemhjt0a87181ci3f